Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877)
:1877
Want to see HK:1877 full AI Analyst Report?
1877 Stock Chart & Stats
HK$27.54
-HK$0.08(-0.74%)
At close: 4:00 PM EST
HK$27.54
-HK$0.08(-0.74%)
Day’s Range― - ―
52-Week RangeHK$17.24 - HK$38.64
Previous CloseN/A
Volume306.00K
Average Volume (3M)7.63M
Market Cap
HK$32.94B
Enterprise ValueHK$36.93B
Total Cash (Recent Filing)HK$4.55B
Total Debt (Recent Filing)HK$5.96B
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding260,295,700
10 Day Avg. Volume5,398,960
30 Day Avg. Volume7,633,399
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$32.17Price Target Upside16.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.4
Revenue Forecast (FY)HK$3.34B
Bulls Say, Bears Say
Bulls Say
High Gross MarginSustained ~78.7% gross margins indicate strong product-level economics typical of biologics, reflecting pricing power and efficient manufacturing for core drugs. Durable high margins provide the structural ability to absorb R&D and SG&A as sales scale and to convert future revenue into operating profits once fixed costs are leveraged.
Integrated R&D-to-commercial ModelOwning capabilities from discovery to commercialization reduces dependence on external partners, preserves value capture, and accelerates go-to-market for successful assets. This vertical integration is a durable competitive advantage in biologics, improving control over quality, timelines and margins over multi-year commercialization cycles.
Moderate Leverage With Sizable EquityDebt-to-equity near 0.69 and a sizable equity base provide a structural cushion and financing flexibility to support ongoing development. Moderate leverage allows room to raise capital or draw on facilities for pipeline progress without immediate solvency stress, assuming improvement in operating cash flow within months.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow imply structural cash burn that requires external funding or asset monetization to sustain operations. Over a multi-month horizon this constrains reinvestment, increases refinancing and dilution risk, and reduces optionality on strategic investments until cash generation turns positive.
Sustained UnprofitabilityConsistent negative operating and net margins (~-35%) show the company has not yet reached operating leverage; ongoing losses pressure ROE and limit self-funding of R&D and commercial expansion. Achieving durable profitability will require sustained revenue scale or material cost restructuring over several quarters.
Rising Leverage And Negative ROEIncreasing leverage combined with negative ROE signals erosion of shareholder value and reduced financial flexibility. If operating losses persist, higher debt amplifies refinancing risk and could force dilutive equity raises or strategic exits for assets, creating structural funding pressure over the medium term.
Shanghai Junshi Biosciences Co., Ltd. Class H News
1877 FAQ
What was Shanghai Junshi Biosciences Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Junshi Biosciences Co., Ltd. Class H lowest stock price was HK$17.24 and its highest was HK$38.64 in the past 12 months.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap?
Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap is HK$32.94B.
When is Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 82 days.
How were Shanghai Junshi Biosciences Co., Ltd. Class H’s earnings last quarter?
Shanghai Junshi Biosciences Co., Ltd. Class H released its earnings results on Apr 27, 2026. The company reported -HK$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.023.
Is Shanghai Junshi Biosciences Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Junshi Biosciences Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai Junshi Biosciences Co., Ltd. Class H pay dividends?
Shanghai Junshi Biosciences Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate?
Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Junshi Biosciences Co., Ltd. Class H have?
Shanghai Junshi Biosciences Co., Ltd. Class H has 260,295,700 shares outstanding.
What happened to Shanghai Junshi Biosciences Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Junshi Biosciences Co., Ltd. Class H reported an EPS of -HK$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.773%.
Which hedge fund is a major shareholder of Shanghai Junshi Biosciences Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Junshi Biosciences Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.67%
12-Months-Change
Fundamentals
Return on Equity
-10.78%
Trailing 12-Months
Asset Growth
37.38%
Trailing 12-Months
Company Description
Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
1877 Stock 12 Month Forecast
Average Price Target
HK$32.17
▲(16.80% Upside)
Technical Analysis
Innovent Biologics
―
Zai Lab Ltd
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---